Assessment of IHC-Ki67 after short-term neoadjuvant hormone therapy in hormone receptor positive breast cancer

Assessment of IHC-Ki67 after short-term neoadjuvant hormone therapy in hormone receptor positive breast cancer - Assessment of IHC-Ki67 after short-term neoadjuvant hormone therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010665

Enrollment

Registered

2013-10-10

Start date

2013-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

2weeks-Neoadjuvant hormone therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non treated primary invasive ductal breast cancers Estrogen receptor or Progesterone receptor positive &#8805; 10% and HER2/FISH test Tumor size &#8805; 10mm

Exclusion criteria

Exclusion criteria: Neoadjuvant chemotherapy Inoperable

Design outcomes

Primary

Measure	Time frame
IHC-Ki67 and gene expression before and after short-term neoadjuvant hormone therapy	—

Countries

Japan

Contacts

Public ContactTakayuki Iwamoto

Okayama University Hospital Breast and Endocrine surgery

xjrtaka@hotmail.com086-235-6502

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026